Customize
Quick Links

Accreditation/
Credit Designation

Physicians' Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC, designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Commercial Support

This activity is supported by an educational grant from AstraZeneca.

About
Accreditation
Privacy Policy
Terms & Conditions
Executive Board
Journal
Faculty Portal
Contact
Facebook
Twitter
LinkedIn
Google +
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 1-609-378-3701

Copyright © 2019
Physicians’ Education Resource ®, LLC.
All rights reserved.

ASCO: Saturday Night Tumor Board: Applying the Evidence to Challenging Scenarios in Patients With NSCLC and EGFR Mutations

ASCO: Saturday Night Tumor Board: Applying the Evidence to Challenging Scenarios in Patients With NSCLC and EGFR Mutations


Saturday, June 1, 2019
Registration: 6:30 PM – 7:00 PM
Program: 7:00 PM – 9:00 PM

Hyatt Regency Chicago
Columbia G-L
151 E. Wacker Dr.
Chicago, IL

Overview

Saturday Night Tumor Board: Applying the Evidence to Challenging Scenarios in Patients With NSCLC and EGFR Mutations is a live symposium to be held adjunct to the annual ASCO meeting in Chicago. This activity will bring together internationally renowned experts in the treatment of patients with non–small cell lung cancer (NSCLC) and mutations in the epidermal growth factor receptor (EGFR) gene. Given that there are now many choices and decision points in the treatment of these patients, this program will seek to improve your ability to leverage appropriate data sets in your clinical practice. Testing and choosing therapy along the disease continuum will be discussed, along with strategies to manage patients with brain metastases. Adverse event management and future directions in the field will also be addressed. Throughout the program, audience participation will be integrated to encourage interaction with faculty and engagement with the content.

Please join us in Chicago for expert advice on successfully navigating therapeutic decision points for patients with NSCLC and EGFR mutations. You won’t want to miss this activity!

Benefits of attending Saturday Night Tumor Board: Applying the Evidence to Challenging Scenarios in Patients With NSCLC and EGFR Mutations:

Participating in this exciting, interactive CME event will provide you with the opportunity to:

  • Gain insights into state-of-the-art molecular testing strategies in patients with NSCLC
  • Improve competence in selecting treatment through multiple lines of therapy for patients with NSCLC and EGFR mutations
  • Learn about managing patients with EGFR mutation–positive NSCLC and brain metastases
  • Expand knowledge of managing treatment-related adverse events in patients with NSCLC and EGFR mutations

Acknowledgment of Commercial Support

This activity is supported by an educational grant from AstraZeneca.

Target Audience

This educational program is directed toward the ASCO audience, primarily medical oncologists. Nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other health care professionals interested in the treatment of cancer are also invited to participate.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

  • Assess the application of liquid-based and tumor-based molecular testing approaches to choose initial and subsequent lines of therapy for patients with advanced, EGFR mutation–positive NSCLC
  • Evaluate clinical data on strategies for the initial management of patients with EGFR mutation–positive NSCLC
  • Discuss clinical data informing the management of acquired resistance and disease progression in patients with EGFR mutation–positive NSCLC
  • Describe management strategies for patients with EGFR mutation–positive NSCLC and brain metastases and/or treatment-related adverse events

Program Chair

Mark G. Kris, MD
Attending, Thoracic Oncology Service
William and Joy Ruane
Chair in Thoracic Oncology
Memorial Sloan Kettering Cancer Center
New York, NY







Become a Member

Forgot Password?
Calendar of Events
SUNMONTUESWEDTHURSFRISAT
     12
3456789
10111213141516
17181920212223
24252627282930
31
Filter By